Introduction on cancer immunology and immunotherapy

Cancer Immunology: A Translational Medicine Context

Volumn , Issue , 2015, Pages 1-8

  Rezaei, Nima ^a,b   Aalaei Andabili, Seyed Hossein ^a,c   Kaufman, Howard L ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943394925     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-662-44006-3_1     Document Type: Chapter

References (38)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1): 10-29.
2. Ries LS, Smith MA, Gurney JG. Cancer Incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda: National Cancer Institute; 1999, Publ No 99-4649.
3. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2008. Bethesda: National Cancer Institute; 2011.
4. Ries L, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2002, National Cancer Institute. Bethesda, http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, 2005.
5. Smith MA, Gurney JG, Ries L. Cancer among adolescents 15-19 years old. In: Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda: National Cancer Institute; 1999, SEER Program NIH Pub No 99-4649.
6. Wikipedia. List of cancer mortality rates: http://en.wikipedia.org/wiki/List_of_cancer_mortality_rates. 10 July 2013, visited at 22 Sept 2013.
7. Lachmann PJ. Tumour immunology: a review. J R SocMed. 1984;77(12): 1023-9.
8. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011; 147(5):992-1009.
9. Biggs PM. Oncogenesis and herpes virus II, Part 2. In: de The G, Epstein MA, zur Hausen H, editors. Epidemiology, host response and control II. Lyon: IARC Publications; 1972. p. 317.
10. Prehn RT. The immune reaction as a stimulator of tumor growth. Science. 1972;176(4031):170-1.
11. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004;113(11): 1515-25.
12. Kersey JH, Spector BD, Good RA. Primary immunodeficiency and malignancy. Birth Defects Orig Artie Ser. 1975;11(1):289-98.
13. Kersey JH, Spector BD, Good RA. Primary immunodeficiency diseases and cancer: the immunodeficiencycancer registry. Int J Cancer. 1973;12:333-47.
14. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancermediated immunosuppression. Cancer Res. 2001; 61(1):237-42.
15. Schlager SI, Ohanian SH, Borsos T. Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid. J Immunol. 1978; 120(2):463-71.
16. Lin YS, Caffrey JL, Lin JW, Bayliss D, Faramawi MF, Bateson TF, et al. Increased risk of cancer mortality associated with cadmium exposures in older Americans with low zinc intake. J Toxicol Environ Health A. 2013;76(1):1-15.
17. Bleyer A, Viny A, Barr R. Introduction. In: Bleyer A, Viny A, Barr R, editors. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. Bethesda: National Cancer Institute; 2006, NIH Pub. No. 06-5767.
18. Greaves MF. Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia. Cancer Res. 1981;41(11 Pt 2):4752-66.
19. Wilczynski JR, Duechler M. How do tumors actively escape from host immunosurveillance? Arch Immunol Ther Exp (Warsz). 2010;58(6):435-48.
20. Lewis M, Lewis G. Strengthen the body and its immune cells. In: Lewis M, Lewis G, editors. Cancera threat to your life OR A chance to control your future. Australia Cancer & Natural Therapy Foundation of Australia; Lewis Publications, New Zealand 2006.
21. Szekeres G, Battyani Z. Immuno-diagnosis of malignant melanoma. Magy Onkol. 2003;47(1): 45-50.
22. Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 1910;3(Surg Sect):1-48.
23. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy revisited. Nat Rev Drug Discov. 2011; 10(8): 591-600.
24. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010;10(12):878-89.
25. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-14.
26. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010; 17(3):718-30.
27. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
28. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8): 1717-25.
29. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190(3):355-66.
30. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-77.
31. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381-5.
32. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005; 115(12): 3623-33.
33. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4.
34. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20): 4099-102.
35. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007; 13(1):54-61.
36. Lesterhuis WJ, de Vries IJ, Aarntzen EA, De Boer A, Scharenborg NM, Van de Rakt M, et al. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer. 2010;103(9):1415-21.
37. Den Brok MH, Sutmuller RP, Van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64(11):4024-9.
38. Brickell PM, Latchman DS, Murphy D, Willi son K, Rigby PW. Activation of a Qa/Tla class I major histocompatibility antigen gene is a general feature of oncogenesis in the mouse. Nature. 1983;306(5945): 756-60.